Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled Study

por Steens, Jean-Marc, Scherrer, Didier, Gineste, Paul, Barrett, P. Noel, Khuanchai, Supparatpino, Winai, Ratanasuwan, Ruxrungtham, Kiat, Tazi, Jamal, Murphy, Robert, Ehrlich, Hartmut
Publicado 2017

Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1: a Phas...

por Rutsaert, Sofie, Steens, Jean-Marc, Gineste, Paul, Cole, Basiel, Kint, Sam, Barrett, P Noel, Tazi, Jamal, Scherrer, Didier, Ehrlich, Hartmut J, Vandekerckhove, Linos
Publicado 2019

Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/o...

por Daien, Claire, Krogulec, Marek, Gineste, Paul, Steens, Jean-Marc, Desroys du Roure, Laurence, Biguenet, Sophie, Scherrer, Didier, Santo, Julien, Ehrlich, Hartmut, Durez, Patrick
Publicado 2022